Anti-idiotypic immunotherapy in follicular lymphoma patients: Results of a long follow-up study

Journal of Immunotherapy

Volumn 31, Issue 3, 2008, Pages 310-312

  Yáñez, Rosa ^a   Barrios, Yvelise ^a   Ruiz, Elena ^a   Cabrera, Rafael ^a   Díaz Espada, Fernando ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Idiotypic vaccination; Lymphoma immunotherapy; Tumor vaccines

Indexed keywords

CYCLOPHOSPHAMIDE; IDIOTYPIC ANTIBODY; PREDNISONE; VINCRISTINE;

ARTICLE; BLOOD ANALYSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LYMPHOMA CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ACTIVE; LYMPHOMA, FOLLICULAR; NEOPLASM CIRCULATING CELLS; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 41149122774     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816a8116     Document Type: Article

References (13)

1. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327:1209-1215.
2. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long term results of a clinical trial. Blood. 1997;89:3129-3135.
3. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177.
4. Timmerman JM, Czerwinsky DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
5. Weng W-K, Czerwinsky DK, Timmerman JM, et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22:4717-4724.
6. Inoges S, Rodríguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98:1292-1301.
7. Barrios Y, Cabrera R, Yañez R, et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica. 2002;87:400-407.
8. Yáñez R, Barrios Y, Cabrera R, et al. Intraclonal variability of VH genes in follicular lymphoma patients who have received anti-idiotypic immunotherapy. J Immunother. 2006;29:61-66.
9. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
10. Barrios Y, Plaza A, Cabrera R, et al. Active idiotypic vaccination in a patient with biclonal follicular lymphoma. Cancer Immunol Immunother. 2001;50:87-92.
11. Hiddeman W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicine, vincristine, and prednisone (CHOP) significantly improves the outcome of patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
12. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
13. Weng W-K, Levy R. Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.